Selection of AmpC beta-lactamase Variants and Metallo-beta-lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.

PMID: 349300342022Spain|Portugal

Key Findings

The study identifies several AmpC beta-lactamase variants and metallo-beta-lactamases (VIM-2, IMP-13, IMP-28) that confer resistance to ceftolozane/tazobactam and ceftazidime/avibactam in MDR/XDR Pseudomonas aeruginosa isolates.

View on PubMed

14gene entries

6mutation entries

AMR Genes

Gene Name	Alleles	Encodes	Confers Resistance To	Organisms	Database	Validation Status
blaIMP	2	Metallo-beta-lactamase	Ceftazidime	Pseudomonas aeruginosa	Reslit	-
blaPDC	7	AmpC beta-lactamase	CeftazidimeCEPHALOSPORIN	Pseudomonas aeruginosa	Card DatabaseReference Gene CatalogReslit	-
blaVIM	1	Metallo-beta-lactamase

AMR Mutations

Gene	Protein Change	Nucleotide Change	Mechanism	Organism	Resistance To	Database	Validation Status
ampC	G214R	-	enhanced cephalosporin resistance	Pseudomonas aeruginosa	Ceftazidime\|Ceftolozane	Reslit	-
ampC	P154L	-	enhanced cephalosporin resistance	Pseudomonas aeruginosa	Ceftazidime\|Ceftolozane	Reslit	-
ampC	F121L	-	enhanced cephalosporin resistance	Pseudomonas aeruginosa	Ceftazidime\|Ceftolozane

Browse Papers

Selection of AmpC beta-lactamase Variants and Metallo-beta-lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.

AMR Genes

AMR Mutations